Medtronic PLC vs uniQure N.V. Ordinary Shares — how do they compare? Medtronic PLC trades at $95.03 (market cap $120.53B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: Medtronic PLC is far larger — about 83.1× uniQure N.V. Ordinary Shares's market cap, and Medtronic PLC pays a 3.06% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MDT | QURE | |
|---|---|---|
Market Cap | $120.53B | $1.45B |
Volume | 49,858,758 | 3,323,243 |
Sector | Health | Health |
52-Week High | $105.35 | $70.59 |
52-Week Low | $73.75 | $9.03 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $139.87B | $707.46M |
Dividend Yield | 3.06% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, 7% revenue growth in Q1 2026, and a 49-year dividend growth streak. Valuation metrics include a P/E of 22.91 and P/S of 3.19. Recent positive news includes FDA clearances for medical devices and raised full-year guidance, supporting investor confidence.
Outlook remains positive with analyst consensus at Buy (61%) and $97.73 price target. Key opportunities include sustained dividend growth and new product approvals, while risks involve debt increase to 31.11% of assets and competitive pressures. The stock's current level near resistance at $93 suggests potential for breakout if earnings momentum continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →